NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

💉 Vaccines

Location

Netherlands

Market Cap

USD 2.08 B

Share Price

USD 18.57

Avg Daily Volume

921,979

Change (1 day)

0.65%

Change (1 year)

-4.96%

Change (YTD)

-27.74%

NewAmsterdam Pharma Company N.V. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2025: USD 0.47

NewAmsterdam Pharma Company N.V. Revenue Per Share is USD 0.47 for the Trailing 12 Months (TTM) ending March 31, 2025, a 497.49% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

NewAmsterdam Pharma Company N.V. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 0.08, a -95.70% change year over year.
NewAmsterdam Pharma Company N.V. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 1.82, a -30.83% change year over year.
NewAmsterdam Pharma Company N.V. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 2.63.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	68
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals 💉 Vaccines

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.